December 15, 2020 - SAN DIEGO, U.S.A., and Louisville, U.S.A.: Antlia Bioscience, Inc. established a research collaboration with Pharmaron, a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry with operations in the U.S., China, and the UK. This collaboration will accelerate the pre-clinical development of a number of Antlia Bioscience’s novel long-acting peptide-based drug candidates.
About Pharmaron: Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry with operations in the U.S., China, and the UK. Please visit www.pharmaron.com.
About Antlia Bioscience, Inc.: Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and pulmonary diseases. We use PASylation® a proprietary and powerful chemistry platform to design novel long-acting peptides with fine-tuned pharmacologic and pharmacokinetic properties to create promising therapeutics for chronic diseases.
December 15, 2020 - SAN DIEGO, U.S.A., and Louisville, U.S.A.: Antlia Bioscience, Inc. established a research collaboration with Pharmaron, a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry with operations in the U.S., China, and the UK. This collaboration will accelerate the pre-clinical development of a number of Antlia Bioscience’s novel long-acting peptide-based drug candidates.
About Pharmaron: Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry with operations in the U.S., China, and the UK. Please visit www.pharmaron.com.
About Antlia Bioscience, Inc.: Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and pulmonary diseases. We use PASylation® a proprietary and powerful chemistry platform to design novel long-acting peptides with fine-tuned pharmacologic and pharmacokinetic properties to create promising therapeutics for chronic diseases.
November 23, 2020 - SAN DIEGO, U.S.A., and STOCKHOLM, Sweden: Antlia Bioscience, Inc., has established a research collaboration with Associate Professor Mikael Adner of the Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Assoc. Prof. Mikael Adner has a keen interest in asthma, allergology, and pulmonary inflammatory pathways causing hyper-responsiveness in the lung. Assoc. Prof. Adner is a well-recognized expert in the pulmonary research field with over 100 peer-reviewed papers published. The collaboration will facilitate the development of Antlia Bioscience’s novel long-acting aerosolized peptide-based therapy for the treatment of pulmonary arterial hypertension, severe asthma, and other pulmonary diseases.
About Karolinska Institutet: Karolinska Institutet is one of the world’s leading medical universities, with a vision to advance knowledge about life and strive towards better health for all. Karolinska Institutet is Sweden’s single largest center of medical academic research. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. Please visit: www.ki.se/en
About Antlia Bioscience, Inc.: Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and metabolic diseases. Using PASylation® and other state-of-the-art techniques, we turn promising peptides into groundbreaking therapies.
October 15, 2020 - SAN DIEGO, U.S.A., and FREISING, Germany: Antlia Bioscience, Inc., a privately-owned biopharmaceutical company located in San Diego, California and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a Strategic Alliance using XL-protein’s proprietary PASylation®technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure. Brian Johnson, Antlia Bioscience’s CEO commented, “chronic heart failure is a significantly unaddressed medical condition and a major public health concern. XL-protein’s PASylation® technology will allow us to safely and effectively translate our peptide into a meaningful therapeutic option for patients with chronic heart failure. “PASylation® is an excellent biological solution for plasma-half extension of therapeutic peptides, and we believe that PASylation® offers a simpler manufacturing process and superior pharmacological properties,” commented Claus Schalper, CEO of XL-protein. “We are excited to work with Antlia Bioscience to further exploit the potential of our technology and to develop new therapeutic options for the treatment of chronic heart failure.” The financial terms of the agreement have not been disclosed.
About PASylation® Technology
'PASylation' involves the genetic fusion or chemical conjugation of a therapeutic protein or pharmaceutically active compound with a conformationally disordered polypeptide of defined sequence comprising the small natural amino acids Pro, Ala, and/or Ser. Due to the biophysical size effect, the typically rapid clearance via renal filtration of the original drug can be retarded by a factor 10-100, depending on the length of the PAS chain. PAS sequences are highly soluble while lacking charges, they are biochemically inert, non-toxic and non-immunogenic, they offer efficient recombinant protein production in a variety of biotechnological host organisms, and they show high stability in blood plasma but are biodegradable by intracellular proteases.
About XL-protein GmbH
XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels.
For more information, please visit: www.xl-protein.com
About Antlia Bioscience, Inc.
Antlia Bioscience is a San Diego-based biotech developing groundbreaking peptide-based therapies to treat cardiovascular and metabolic diseases. Using PASylation® and other state-of-the-art techniques, we turn promising peptides into groundbreaking therapies.
For more information, please visit: www.antliabio.com
Copyright © 2023 Antlia Bioscience, Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.